SEC Tracker
Get the app

Surrozen SRZN

Surrozen gets FDA clearance for SZN-8141 IND

Form
8-K
Filed
Importance
Routine
  1. FDA cleared SZN-8141 IND on Oct 2, 2026
  2. First patient dosing in DUET study expected Q4 2026
  3. Second closing of private placement expected Oct 20, 2026
  4. Proceeds to fund SZN-8141 development

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Surrozen files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Sutro Biopharma STRO public float $60M, Jun 30, 2025
  2. PDS Biotechnology PDSB public float $60M, Jun 30, 2025
  3. iBio IBIO public float $58M, Dec 31, 2025
  4. Medicinova MNOV public float $62M, Jun 30, 2025
  5. Lifevantage LFVN public float $64M, Dec 31, 2025